|
4. Dépistage, diagnostic et pronostic
|
|
|
|
4.12 Biopsies liquides
|
|
|
Liquid Biopsy May Predict Risk of Breast Cancer Returning Years Later [NCI]
|
|
|
|
|
|
“This
[finding] is not something that should change practice now,” said lead
investigator Kathy Miller, M.D., of Indiana University Melvin and Bren
Simon Cancer Center. “But it gives us the potential for future clinical
trials that identify patients at higher risk [of late recurrence] and
study whether having that information could change treatment and improve
outcomes.”
|
|
|
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
5.12 Immunothérapies
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
5.12.6 Immunothérapies - AMM
|
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
AbbVie, Tolero team up to test Venclexta combo in AML [FierceBiotech]
|
|
|
|
|
|
Alvocidib
inhibits CDK9, which controls the expression of the survival factor
MCL-1, which, along with BCL-2, is co-opted by cancer cells to avoid
cell death. Tolero and AbbVie reckon that Venclexta and alvocidib might
complement each other as previous studies have shown that cancer cells
can resist BCL-2 inhibition by using MCL-1 to prevent cell death.
|
|
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA,...)
|
|
|
|
|
Ribociclib Approval Expanded for Some Women with Advanced Breast Cancer [NCI]
|
|
|
|
|
|
The
new approvals for ribociclib were the first granted through a new FDA
pilot program launched earlier this year called Real-Time Oncology
Review. The program allows FDA to begin reviewing a drug after results
from trials are first available but before a company has officially
submitted an approval application.
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
6.1 Observation
|
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
6.4 Médico-éco
|
|
|
A Chinese Pharmacist Found Out He Had Cancer. Then He Vanished. [NY Times]
|
|
|
|
|
|
Nearly
a decade after the rollout of an ambitious $130 billion health care
reform plan, millions of people cannot afford the treatments they need
for serious illnesses. Insurance coverage of major illnesses like cancer
is low, and many cancer-related drugs are not covered at all. Local
governments, lacking cash, sometimes fail to reimburse patients.
|
|
|
|
|
|
|
6.5 Médecines alternatives
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
6.7.1 IA/bioinformatique
|
|
|
|
6.7.2 Applis
|
|
|